Immunocore (IMCR) Expected to Announce Earnings on Wednesday

Immunocore (NASDAQ:IMCR) is expected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $87.63 million for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Immunocore Stock Up 0.2 %

IMCR opened at $29.99 on Tuesday. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The firm has a 50 day moving average price of $29.99 and a 200-day moving average price of $32.03. Immunocore has a twelve month low of $27.69 and a twelve month high of $72.56. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -31.57 and a beta of 0.77.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on IMCR shares. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price target (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Needham & Company LLC reissued a “buy” rating and issued a $71.00 target price on shares of Immunocore in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Monday, January 27th. Finally, Mizuho downgraded shares of Immunocore from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $72.00 to $38.00 in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $65.64.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.